UNITED LABORATORIES (03933.HK) announced that the atopic dermatitis indication for the dupilumab biosimilar injection developed by its wholly owned subsidiary, Zhuhai United, has o... Open a new ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...

Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently. Tralokinumab caused more frequent injection site ...